𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cyclic AMP: a selective modulator of NF-κB action

✍ Scribed by Sarah Gerlo; Ron Kooijman; Ilse M. Beck; Krzysztof Kolmus; Anneleen Spooren; Guy Haegeman

Publisher
Springer
Year
2011
Tongue
English
Weight
855 KB
Volume
68
Category
Article
ISSN
1420-682X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A novel NF-κB inhibitor DHMEQ selectivel
A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo
✍ Mariko Watanabe; Md. Zahidunnabi Dewan; Takamitu Okamura; Masataka Sasaki; Kinji 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 453 KB

Multiple myeloma (MM) is a fatal lymphoid malignancy that is incurable with conventional modalities of chemotherapy. Strong and constitutive activation of nuclear factor kappa B (NF-kappaB) is a common characteristic of MM cells. In our study we successfully target NF-kappaB with a novel NF-kappaB i

Simvastatin, 3-hydroxy-3-methylglutaryl
Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-κB ligand through modulation of NF-κB pathway
✍ Kwang Seok Ahn; Gautam Sethi; Madan M. Chaturvedi; Bharat B. Aggarwal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 631 KB

## Abstract Simvastatin, an inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase, is a cholesterol‐lowering drug that may play a role in bone metabolism through a mechanism that is not fully understood. Recently, receptor activator of NF‐κB ligand (RANKL), a member of the TNF superfamily, h